Brief · Use case · Pharmacovigilance

Benefit-Risk Position Assessment.

LiveAssessment

Judge whether a marketed medicine's benefit-risk balance holds after new safety data, how the evidence grades and where the position is weakest.

PositionThe benefit-risk balance remains favourable

TriggerA new safety finding from post-marketing reports

ExpertHead of Pharmacovigilance

Not askedA recommended action

LengthComprehensive

Benefit-Risk Position Assessment is a ready-made use case for Pharmacovigilance. It ships under the Assessment template.

For pharmacovigilance and medical safety leads. You get a stated position with its confidence, the evidence graded with the reason for each rating, the uncertainties named by cause and type and what would overturn the view. Claims are cited or marked as gaps.

Add it to your library to reuse from New → From template. Edit the saved copy in your library on the service form.

The decision

How well supported is the position that the benefit-risk balance of a marketed medicine remains favourable after a new safety finding from post-marketing reports?

What the assessment examines

A benefit-risk position is a judgment about two kinds of evidence at once. The assessment sets out each, the way regulators ask, and says how the new finding changes the balance.

Part of the position	What the assessment examines	Where it looks
The new safety finding	What the reports show and what they cannot show. FDA states that a report in its system does not mean the product caused the event, and that the data cannot give incidence.^{3U.S. Food and Drug Administration. Questions and Answers on FDA’s Adverse Event Reporting System (FAERS).}	FDA’s materials on its adverse event reporting system.
The benefits	The favorable effects on which the product was authorized, and how certain they remain.^{1European Medicines Agency. ICH E2C(R2): Periodic benefit-risk evaluation report, EMA/CHMP/ICH/544553/1998.}	The periodic benefit-risk evaluation, which weighs new information against cumulative data.
The balance	How benefit and risk are weighed together, in a structured framework that documents the evidence and the uncertainties.^{2U.S. Food and Drug Administration. Benefit-Risk Assessment for New Drug and Biological Products. Draft guidance, September 2021.}	FDA’s benefit-risk assessment guidance for new drug and biological products.

What the assessment does

The report format regulators use. ICH E2C(R2), the guideline on the periodic benefit-risk evaluation report, is intended as a common standard for periodic benefit-risk evaluation of marketed products. It asks for new information in the reporting interval to be judged against cumulative information, and the assessment follows that approach.^{1European Medicines Agency. ICH E2C(R2): Periodic benefit-risk evaluation report, EMA/CHMP/ICH/544553/1998.}

A structured framework. FDA’s framework organizes the benefit-risk assessment so that the evidence and the uncertainties for each dimension are documented. The assessment uses that organization, and notes where the guidance is a draft or a final version.^{2U.S. Food and Drug Administration. Benefit-Risk Assessment for New Drug and Biological Products. Draft guidance, September 2021.}

What the finding can and cannot show. A spontaneous report is a signal. It is not a rate and it does not establish causation. The assessment grades the finding by what it can support and names what further evidence would strengthen or weaken it.^{3U.S. Food and Drug Administration. Questions and Answers on FDA’s Adverse Event Reporting System (FAERS).}

The strongest objection. The objection is that the new finding has changed the balance and the position has not caught up. The assessment restates it fairly and answers it with the benefit evidence and with the size and quality of the finding.

Recommended length

Comprehensive

The position will be challenged by people who hold another view. Comprehensive adds the alternatives considered and the reasoning behind the support, which is what a challenger asks for.

You can pick another length on the form. The other two stay available.

Assumptions the assessment checks

The assessment states the assumptions the position rests on and says which one would hurt most if it failed. Examples for this position:

The benefit evidence at authorization still describes the treated population.
The new reports concern the same product and population as the benefit data.
No other source of safety information is missing.

Standards, guidance and sources

Benefit-risk evaluation

ICH E2C(R2), Periodic Benefit-Risk Evaluation Report: Step 4 in November 2012, in effect in the EU from 1 January 2013.^{1European Medicines Agency. ICH E2C(R2): Periodic benefit-risk evaluation report, EMA/CHMP/ICH/544553/1998.}
FDA, Benefit-Risk Assessment for New Drug and Biological Products (draft September 2021; FDA materials indicate a final version in 2023).^{2U.S. Food and Drug Administration. Benefit-Risk Assessment for New Drug and Biological Products. Draft guidance, September 2021.}

Limits of spontaneous reports

FDA, Questions and Answers on the FDA Adverse Event Reporting System.^{3U.S. Food and Drug Administration. Questions and Answers on FDA’s Adverse Event Reporting System (FAERS).}

The decision practice behind the memo itself is on the template page.

What gets flagged

Any statement of causation drawn from reports alone, any benefit evidence older than the new finding, and any missing source of safety data.

What arrives

The position
The basis
Why the evidence supports it
The strongest objection, answered
Other views considered
Where it is weak

What it will not do

It does not recommend an action. A Decision Memo takes the assessment as its starting point.

It is not a regulatory benefit-risk evaluation, and it does not decide whether a label change or other action is needed.

It does not recommend an action. An assessment says how well a position is supported; a Decision Memo recommends what to do.

Certainty ratings are analyst judgment from an AI specialist, not measurements, and the reason for each is on the page so you can disagree with it.

It does not settle a question the evidence leaves open. Where the evidence is thin, the assessment says so and says what would settle it.

References

[1] European Medicines Agency. ICH E2C(R2): Periodic benefit-risk evaluation report, EMA/CHMP/ICH/544553/1998. Known from EMA’s page listing and search excerpts; the guideline was not read in full.
[2] U.S. Food and Drug Administration. Benefit-Risk Assessment for New Drug and Biological Products. Draft guidance, September 2021. The link is the September 2021 draft. FDA materials found by search indicate a final version issued in October 2023 under a slightly different title; check the current version.
[3] U.S. Food and Drug Administration. Questions and Answers on FDA’s Adverse Event Reporting System (FAERS). The limits are as stated in FDA’s FAERS materials listed by search; the page was not opened from our tools.

Links checked 9 October 2026

These are the sources the template drew on. None of their authors or issuers has reviewed it.

About the Brief service

A Brief is a written answer from one specialist, at the depth you asked for. It arrives with its sources, and it closes by saying plainly what would change the conclusion. Nothing is hidden behind a summary, and anything the expert could not source is marked as a gap rather than filled in.

To edit a saved template, open New → Brief → From template, or the library rail on the service form.